Skip to main content
. 2024 Aug 20;13:e53821. doi: 10.2196/53821

Figure 3.

Figure 3

Reported fistula discharge pre- and post-HBO2 therapy in patients with Crohn disease who had complete pre- and post-HBO2 data. The sensitivity analyses results are follows: best case (25/33, 76% improved; P<.001), worst case 10/33, 30% improved; P=.33), and average case (18/33, 55% improved; P=.08).